Literature DB >> 18362836

Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.

Shuichi Mitsunaga1, Taira Kinoshita, Takahiro Hasebe, Toshio Nakagohri, Masaru Konishi, Shinichiro Takahashi, Naoto Gotohda, Atsushi Ochiai.   

Abstract

OBJECTIVES: Systemic disorder is a characteristic of advanced pancreatic cancer. Clinical prognostic factors in earlier disease state than terminal stage are expected to be sensitive markers for the foresight of systemic disorder. This study aimed to find the associations between these sensitive markers and morphological factors of primary tumor that may indicate finding a way of pathogenesis of systemic disorder.
METHODS: The current study examined 75 patients who received macroscopic curative resection for pancreatic cancer in our institution as follows: (1) identification of clinical prognostic factors at initial recurrence after resection of primary tumor and (2) analysis of correlations between clinical prognostic factors and histological findings in primary tumor.
RESULTS: Important prognostic factors were peritoneal dissemination and serum levels of carbohydrate antigen 19-9 and cholinesterase. Only low levels of serum cholinesterase correlated to nerve plexus invasion in histological findings of primary tumor. Patients with low cholinesterase levels show systemic disorder, including poor performance status, anemia, and hypoalbuminemia.
CONCLUSIONS: Nerve invasion may thus result in low functional state of the liver followed by systemic disorder. This mechanism may be useful for elucidating cancer cachexia in future studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362836     DOI: 10.1097/MPA.0b013e31815b6b2b

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  16 in total

1.  Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma.

Authors:  Bo Zhang; Cheng Shen; Jie Jin; Yi Song; Zheng Zhao; Xiaochun Zhang; Gang Wang; Yu Fan; Yue Mi; Shuai Hu; Yun Cui; Liqun Zhou; Zhisong He; Wei Yu; Wenke Han
Journal:  Int Urol Nephrol       Date:  2016-08-23       Impact factor: 2.370

2.  The impact of low serum cholinesterase levels on survival in patients with colorectal cancer.

Authors:  Yasuhiro Takano; Koichiro Haruki; Shu Tsukihara; Daisuke Ito; Hironori Kanno; Kyonsu Son; Nobuyoshi Hanyu; Ken Eto
Journal:  Int J Colorectal Dis       Date:  2022-03-15       Impact factor: 2.796

3.  Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.

Authors:  Takuya Koie; Chikara Ohyama; Shingo Hatakeyama; Atsushi Imai; Takahiro Yoneyama; Yasuhiro Hashimoto; Tohru Yoneyama; Yuki Tobisawa; Shogo Hosogoe; Hayato Yamamoto; Masato Kitayama; Kazuyoshi Hirota
Journal:  Int J Clin Oncol       Date:  2015-07-30       Impact factor: 3.402

4.  [Clinical and laboratory characteristics of juvenile myelomonocytic leukemia].

Authors:  Yuan-Yuan Wu; Sheng-Yang Cai; Wei Huang; Si-Si Li; Wei Li; Ao Dong
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

5.  Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Authors:  Tomofumi Miura; Shuichi Mitsunaga; Masafumi Ikeda; Izumi Ohno; Hideaki Takahashi; Hidetaka Suzuki; Ai Irisawa; Takeshi Kuwata; Atsushi Ochiai
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

6.  Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib.

Authors:  Haruhiko Takeda; Hiroki Nishikawa; Eriko Iguchi; Yoshiaki Ohara; Azusa Sakamoto; Keiichi Hatamaru; Shinichiro Henmi; Sumio Saito; Akihiro Nasu; Hideyuki Komekado; Ryuichi Kita; Toru Kimura; Yukio Osaki
Journal:  Mol Clin Oncol       Date:  2012-12-03

7.  Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma.

Authors:  Ana Cristina Castillo-González; Susana Nieto-Cerón; Juan Pablo Pelegrín-Hernández; María Fernanda Montenegro; José Antonio Noguera; María Fuensanta López-Moreno; José Neptuno Rodríguez-López; Cecilio J Vidal; Diego Hellín-Meseguer; Juan Cabezas-Herrera
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

8.  Butyrylcholinesterase as a prognostic marker: a review of the literature.

Authors:  Lidia Santarpia; Ilenia Grandone; Franco Contaldo; Fabrizio Pasanisi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-06       Impact factor: 12.910

Review 9.  Pancreatic cancer cachexia: a review of mechanisms and therapeutics.

Authors:  Carlyn R Tan; Patrick M Yaffee; Laith H Jamil; Simon K Lo; Nicholas Nissen; Stephen J Pandol; Richard Tuli; Andrew E Hendifar
Journal:  Front Physiol       Date:  2014-03-03       Impact factor: 4.566

10.  Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy.

Authors:  Takuya Koie; Chikara Ohyama; Jotaro Mikami; Hiromichi Iwamura; Naoki Fujita; Tendo Sato; Yuta Kojima; Ken Fukushi; Hayato Yamamoto; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Masato Kitayama; Kazuyoshi Hirota
Journal:  ScientificWorldJournal       Date:  2014-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.